Sandoz launches generic versions of two Merck & Co. solutions
PRINCETON, N.J. Sandoz has introduced generic versions of Cosopt and Trusopt, Novartis’ generics division announced Friday.
Merck & Co. makes the branded versions of Cosopt (dorzolamide and timolol sterile ophthalmic solution) and Trusopt (dorzolamide ophthalmic solution). Both are used to treat open-angle glaucoma and ocular hypertension.
Sandoz will market dorzolamide in the 20-mg-per-mL strength and dorzolamide/timolol with respective strengths of 20 mg per mL and 5 mg per mL.
Dorzolamide had U.S. sales of $49.5 million, and dorzolomide/timolol had sales of $323.9 million in 2008, according to IMS Health data.
Take Care clinics open in Arizona, Illinois
CONSHOHOCKEN, Pa. Take Care Health Systems, which is owned by Walgreens, has announced the opening of two clinics in Chandler, Ariz., and Oak Lawn, Ill.
The new openings make 17 Take Care Clinics in the Phoenix market and 34 clinics in the Chicago market.
In total, the company operates 334 clinics in 35 markets throughout 19 states.
FDA approves new Sanofi-Aventis insulin pen
BRIDGEWATER, N.J. The Food and Drug Administration has approved a new insulin pen from Sanofi-Aventis, the drug maker announced Thursday.
Apidra SoloSTAR (insulin glulisine [rDNA origin]) is a prefilled, disposable insulin pen containing the fast-acting insulin analog Apidra. Apidra is used to improve glycemic control in patients aged 4 and older with Type 1 and Type 2 diabetes. Its approval follows the 2007 approval and launch of Lantus SoloSTAR (insulin glargine [rDNA origin]).
“People with diabetes have to contend with the challenges of carbohydrate counting, regular blood pressure monitoring and careful administration of their insulin,” Sanofi-Aventis U.S. VP metabolism marketing Angela Moskow stated. “Apidra SoloSTAR represents another innovation introduced by Sanofi-Aventis that offers patients a convenient option for administering their Apidra.”